A team of researchers studying genetic data to identify hormone responses in a population of Mexican Americans with prediabetes, Type 2 diabetes, and obesity recently received a $3.5 million grant to fund a five-year study set to begin in late 2021.
Data show racial disparities in type 1 diabetes treatment and outcomes in non-Hispanic Black (NHB) children in the US. NHB children are less likely to be treated with diabetes technology, have poorer glycemic control and higher rates of diabetes complications and diabetes-related mortality than non-Hispanic white children. There is much to be done to ensure equitable care, but as yet, structural racism has not been a focus.
In a new study, published in the Journal of the American Chemical Society, Matthew Webber, associate professor of chemical and biomolecular engineering, is rethinking the traditional use of glucagon as an emergency response by administering it as a preventive measure.
Newborns at risk for Type 1 diabetes because they were given antibiotics may have their gut microorganisms restored with a maternal fecal transplant, according to a Rutgers study.
A novel therapeutic may halt rapid kidney function in some type 1 diabetic kidney disease patients.
By mapping its genetic underpinnings, researchers at University of California San Diego School of Medicine have identified a predictive causal role for specific cell types in type 1 diabetes, a condition that affects more than 1.6 million Americans.
2021 marks 100 years since researchers identified insulin, a hormone produced by the pancreas that regulates the amount of glucose, or sugar, in the blood. Soon after, insulin was shown to be effective in lowering blood glucose in humans with…
One in five adults with type 1 diabetes who require in-hospital treatment of the life-threatening condition diabetic ketoacidosis has an unplanned repeat hospital visit within a month and is twice as likely to die during the second hospitalization, a new study finds. The results, which will be presented at ENDO 2021, the Endocrine Society’s annual meeting, also identified several factors that increased the readmission risk for these patients.
Children with poorly controlled type 1 diabetes have a 10 times higher risk of COVID-19-related complications and death compared to those with well-controlled diabetes, according to a study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.
People with type 1 diabetes can improve their blood sugar control while reducing time with low blood sugar, or hypoglycemia, using Insulet Corporation’s Omnipod 5 Automated Insulin Delivery System compared to their standard insulin therapy. Results from an industry-sponsored study of the latest Omnipod, the first tubeless, wearable insulin pump, will be presented at ENDO 2021, the Endocrine Society’s annual meeting.
Blood glucose levels improved among children and teens with type 1 diabetes during the first 12 weeks of COVID-19 lockdown in the United Kingdom, according to a study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.
Advancements in diabetes technology have improved quality of life and glycemic control in children with type 1 diabetes. However, data show that a subset of children is being left behind. Those from low-income families and non-Hispanic Black (NHB) children are not experiencing benefits associated with technological advances, and are at higher risk for diabetes complications and adverse outcomes through ongoing poor glycemic control.
In older people with type 1 diabetes, damage to the retina may be linked to memory problems and other cognitive conditions.BOSTON – (December 31, 2020) – As they age, people with diabetes are more likely to develop Alzheimer’s disease and other cognitive disorders than are people without diabetes. Scientists at Joslin Diabetes Center now have shown that routine eye imaging can identify changes in the retina that may be associated with cognitive disorders in older people with type 1 diabetes.
Researchers at the University of Utah School of Medicine have identified a new therapeutic target to treat patients with type 1 diabetes. The study, which will be published December 9 in the Journal of Experimental Medicine (JEM), reveals that inhibiting a protein called OCA-B protects mice from type 1 diabetes by limiting the activity of immune cells that would otherwise destroy the pancreas’ insulin-producing β cells.
Type 1 diabetes (T1D) is the third most common pediatric chronic disease in the United States, and the risk of the disease has risen sharply in non-Hispanic Black (NHB) children in the last 20 years, data show. Ironically, the significant advances in T1D therapeutics over recent years, especially new technologies, may have exacerbated racial disparities in diabetes treatment and outcomes
A collaboration to accelerate research to cure type 1 diabetes and improve lives.
More than 34 million people in the U.S, or 10.5% of the population, have diabetes, according to the Centers for Disease Control and Prevention. And as many as 7 million more Americans have the disease and don’t know it. Diabetes is the seventh-leading cause of death in the country..
Transplanting cadaver pancreatic islets is a promising therapy for Type 1 diabetes, but a reactivated autoimmunity means low graft viability after five years. Research now shows that a protective coating of two biopolymers can delay allograft and autoimmune-mediated rejection in mouse models of T1D.
It’s long been thought that having “autoreactive” T cells in the pancreas was a sure sign of type 1 diabetes. Yet a new study led by scientists at La Jolla Institute for Immunology (LJI) shows that even healthy people have these cells lurking in the pancreas—in surprisingly high numbers.
Insulin pumps are widely used in the management of type 1 diabetes (T1D) and reviews have shown insulin pump therapy to be associated with improved glycemic control, fewer severe hypoglycemia events, and improved quality of life. Yet, non-Hispanic white children (NHW) are more than twice as likely as non-Hispanic Black children (NHB) to use this technology.
A study led by UC Davis Health researchers uncovered that even one severe episode of diabetic ketoacidosis (DKA) in children newly diagnosed with type 1 diabetes is linked to cognitive problems; and among children with a previous diagnosis, repeated DKA exposure predicted lower cognitive performance after accounting for glycemic control.
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM). The challenges of managing multiple doses of daily insulin administration, blood glucose monitoring, dietary and exercise requirements, can make self-care difficult and complicate outcomes. Adolescents with T1DM often have poorer diabetes outcomes than others, indicating that glucose control is difficult for them to maintain.
Researchers at the Georgia Institute of Technology and University of Missouri developed a new microgel drug delivery method that could extend the effectiveness of pancreatic islet transplantations — from several years to possibly the entire lifespan of a recipient.
A new artificial pancreas system can prevent hypoglycemia—episodes of dangerously low blood sugar—during and after heavy exercise in people with type 1 diabetes, according to a small study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.
An artificial pancreas originally developed at the University of Virginia Center for Diabetes Technology safely and effectively manages blood sugar levels in children ages 6 to 13 with type 1 diabetes, a national clinical trial has found.
Blocking nerve signals to the pancreas could stop patients from ever developing type 1 diabetes.
Getting more sleep, and establishing a regular sleep schedule, is a common recommendation for maintaining and improving health, including for people with Type 1 diabetes. Short sleep patterns may affect how the body uses insulin, and irregular sleep schedules can affect glucose through changes in one’s circadian rhythm or biological clock.
Researchers have discovered a new drug candidate that offers a major advance to treat diabetes. Tested on human and mouse pancreatic islets, mouse and rat cell cultures and animal models of Type 1 and Type 2 diabetes, the drug significantly improved four detrimental characteristics of diabetes.
Albert Einstein College of Medicine has received a $9.5 million, five-year grant from the National Institutes of Health (NIH) to support the Einstein-Mount Sinai Diabetes Research Center (ES-DRC). The multi-institutional center is a leader in basic, translational, clinical, and community-based research and training in type 1 and type 2 diabetes, obesity, and other metabolic disorders.
Children with type 1 diabetes have a less desirable gut microbiome composition which may play a role in the development of the disease, according to new research published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.
Largest US database of pregnant women with type 1 diabetes provides a first-time, big picture view of mother’s health, and neonatal and delivery outcomes.
The analysis found a threefold increase in insulin pump use at the end of the study period, compared to the start of the study, but A1c levels remained steady across the 13-year period.
Over time the study showed a trend toward pre-pregnancy obesity and unhealthy maternal weight gain.
Historically, half or more of people with type 1 diabetes develop kidney disease, which frequently progresses to kidney failure requiring hemodialysis or a kidney transplant for survival. Progression of kidney disease in type 1 diabetes is correlated with increased amounts of uric acid. A multi-institution randomized clinical trial of a drug used to control uric acid did not show the desired clinical benefits, but did give a very clear answer to an important scientific question.
Fewer than one in five adolescents and young adults with type 1 diabetes are successful in achieving the recommended 2019 A1C goal of below 7.5%, and the overwhelming majority fail to achieve the 2020 target of less than 7%. But young people who use continuous glucose monitoring (CGM) devices can significantly improve their overall blood glucose control, without increasing severe low or high glucose levels, according to findings from a 6-month, multi-center clinical trial. And both severe hypoglycemia (low glucose) and hyperglycemia (high glucose) can lead to emergency care and hospitalization.
Access the latest in diabetes, prediabetes and cardiometabolic care at the Virtual ADCES 2020 Annual Conference from Thursday, Aug. 13 to Sunday, Aug. 16.
Results from a six-month, multi-site clinical trial called the Wireless Innovation for Seniors with Diabetes Mellitus (WISDM) Study Group have been published by the Journal of the American Medical Association (JAMA).
Seven leading diabetes organizations issued a consensus report today highlighting the value of diabetes self-management education and support (DSMES) services as part of comprehensive diabetes medical care. The report provides compelling evidence for the need for increased utilization of DSMES, four key times that DSMES is most beneficial, and specific recommendations for both clinicians and health systems to increase access to and participation in DSMES services.
There’s a higher case fatality rate in type 1 than type 2 diabetes, which suggests different mechanisms for heart failure might be involved in type 1 diabetes.” Given the burden of heart failure in type 1 diabetes, the early identification of patients at particular risk is of importance.
The framework for the AADE7 Self-Care Behaviors were recently published, highlighting changes in diabetes care and management.
Scientists at St. Jude Children’s Research Hospital mapped the epigenetic controls on T cells, which could aid Type 1 diabetes diagnosis and treatment, as well as cancer immunotherapy.
Removing a gene from the cells that produce insulin prevents mice from developing Type 1 diabetes by sparing the cells an attack from their own immune system, a new UW–Madison study shows.
The insulin-producing beta cells in the pancreas unwittingly produce a signal that may aid their own demise in Type 1 diabetes, according to a study of the lipid signals that drive macrophage cells in the body to two different phenotypes of activated immune cells.
Researchers at the Icahn School of Medicine at Mount Sinai have discovered a novel combination of two classes of drugs that, together, cause the highest rate of proliferation ever observed in adult human beta cells—the cells in the pancreas that produce insulin—without harming most other cells in the body. The result is an important step toward a diabetes treatment that restores the body’s ability to produce insulin.
Researchers found, in mice, that changes in DNA sequence can trigger the chromosomes to misfold in a way that puts one at a heightened risk for Type 1 diabetes. The study revealed that differences in DNA sequences dramatically changed how the DNA was folded inside the nucleus, ultimately affecting the regulation of genes linked to the development Type 1 diabetes.
Kellie Antinori-Lent, MSN, RN, ACNS-BC, BC-ADM, CDCES, FADCES was officially recognized last week at the meeting of the board of directors as the 2020 president of the newly rebranded Association of Diabetes Care & Education Specialists (ADCES).
The former American Association of Diabetes Educators is now the Association of Diabetes Care & Education Specialists (ADCES). The rebranding reflects the association’s shift from referencing the specialty title as “diabetes educator” to the more comprehensive “diabetes care and education specialist.” The new title more accurately signifies the range of expertise diabetes care and education specialists provide to people with diabetes, prediabetes and cardiometabolic conditions, the health care system, payers and providers.
As the new year approaches, AADE suggests the following ways for people with diabetes to start the year healthy and stick with it.
Essentially all patients living with type 1 diabetes experience “diabetes burnout” at some time or other. What is diabetes burnout, what factors contribute to the problem, and what can patients and nurses do about it? Those questions are addressed in a descriptive study in the December issue of the American Journal of Nursing. The journal is published in the Lippincott portfolio by Wolters Kluwer.
A Mayo Clinic-led study involving 3,276 patients has found that people with inflammatory bowel disease, Type 1 diabetes or blood clots may be at increased risk of developing rheumatoid arthritis. The study, published in Mayo Clinic Proceedings, also found that people who have rheumatoid arthritis are at increased risk of developing heart disease, blood clots and sleep apnea.
The American Association of Diabetes Educators (AADE) and the American Association of Nurse Practitioners (AANP) have partnered to release a new tool kit that guides healthcare professionals in the implementation of a professional continuous glucose monitoring (CGM) program within their health systems.
A multi-center randomized clinical trial evaluating a new artificial pancreas system — which automatically monitors and regulates blood glucose levels — has found that the new system was more effective than existing treatments at controlling blood glucose levels in people with type 1 diabetes.The study showed that the system improved participants’ blood glucose control throughout the day and overnight.